Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Molecularly targeted agents which inhibit the mammalian target of rapamycin (mTOR) pathway
and/or circumvent p53 in the induction of apoptosis are exciting potential targets in ovarian
cancer. Metformin is a biguanide, widely used in the treatment of type 2 diabetes mellitus,
that has shown anti-cancer activity in preclinical studies. The main mechanism of metformin's
effect is mTOR pathway inhibition and, in addition, it has been shown to circumvent
p53-induced apoptosis making it an exciting, potentially effective drug in ovarian cancer.